These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 3343304

  • 1. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.
    Barry AL, Jones RN.
    J Clin Microbiol; 1988 Jan; 26(1):13-7. PubMed ID: 3343304
    [Abstract] [Full Text] [Related]

  • 2. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN, Barry AL, Thornsberry C, Wilson HW.
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [Abstract] [Full Text] [Related]

  • 3. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.
    Fass RJ, Gregory WW, D'Amato RF, Matsen JM, Wright DN, Young LS.
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2256-9. PubMed ID: 2073118
    [Abstract] [Full Text] [Related]

  • 4. Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.
    Bradford PA, Sanders CC.
    Antimicrob Agents Chemother; 1992 Feb; 36(2):394-400. PubMed ID: 1605604
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.
    Jones RN, Barry AL, Packer RR, Gregory WW, Thornsberry C.
    J Clin Microbiol; 1987 Sep; 25(9):1725-9. PubMed ID: 3498740
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.
    Eliopoulos GM, Klimm K, Ferraro MJ, Moellering RC.
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):624-6. PubMed ID: 2506024
    [Abstract] [Full Text] [Related]

  • 8. In-vitro activity of cefoperazone-sulbactam against Bacteroides species.
    Souza Dias MB, Jacobus NV, Tally FP.
    J Antimicrob Chemother; 1986 Oct; 18(4):467-71. PubMed ID: 3021709
    [Abstract] [Full Text] [Related]

  • 9. Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.
    Hardy DJ, Barry AL, Fuchs PC, Gerlach EH, McLaughlin JC, Pfaller MA.
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):926-30. PubMed ID: 1486889
    [Abstract] [Full Text] [Related]

  • 10. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.
    Jones RN, Barry AL.
    J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843
    [Abstract] [Full Text] [Related]

  • 11. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH, Hu YJ.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):595-600. PubMed ID: 28789493
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM, Finegold SM.
    Antimicrob Agents Chemother; 1988 Mar 01; 32(3):403-6. PubMed ID: 3364960
    [Abstract] [Full Text] [Related]

  • 13. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.
    Barry AL, Thornsberry C, Jones RN, Gavan TL.
    Rev Infect Dis; 1985 Mar 01; 7 Suppl 4():S594-604. PubMed ID: 3909316
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.